Repligen Corp (NAS:RGEN)
$ 169.69 -2.09 (-1.22%) Market Cap: 9.48 Bil Enterprise Value: 9.56 Bil PE Ratio: 678.76 PB Ratio: 4.81 GF Score: 93/100

Repligen Corp at JPMorgan Healthcare Conference Transcript

Jan 09, 2024 / 10:15PM GMT
Release Date Price: $173.14 (-2.11%)
Rachel Marie Vatnsdal Olson
JPMorgan Chase & Co, Research Division - Analyst

Perfect. Good afternoon, everyone. This is Rachel Vatnsdal with the Life Science Tools and Diagnostics team. I'm joined today by Tony Hunt, CEO of Repligen. So this presentation will be 40 minutes. The first 20 minutes or so will be a presentation, followed by 20 minutes of Q&A. If any of you in the audience have questions, please feel free to either submit them on the app or you can ping me and reach out directly. With that, I will pass it off to Tony.

Anthony J. Hunt
Repligen Corporation - CEO & Director

Great. Thanks, Rachel, and great to be here and appreciate getting an opportunity to talk about Repligen at JPMorgan again. I'm going to spend maybe 5 minutes, trying to address maybe some of the -- what's happening in the bioprocessing industry in 2023. I'm not going to give guidance on 2024, so sorry on disappointing people on that one. But I do think that it's important kind of to get our perspective on where we think the bioprocessing industry is as we jump into

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot